Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Soe, Lin H, Wurz, Gregory T, Kao, Chiao-Jung, DeGregorio, Michael W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792833/
https://www.ncbi.nlm.nih.gov/pubmed/24109197
http://dx.doi.org/10.2147/IJWH.S39146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792833/
https://www.ncbi.nlm.nih.gov/pubmed/24109197
http://dx.doi.org/10.2147/IJWH.S39146

Ejemplares similares